Tirzepatide: Dual Incretin Agonism and Structural Basis

A GIP peptide, not a GLP-1 peptide

Tirzepatide is built on the native GIP sequence, with substitutions introducing GLP-1 receptor activity. This origin matters: it is a GIP analog that also engages GLP-1, rather than a GLP-1 analog with GIP activity added.

Like semaglutide it carries a C20 fatty diacid for albumin binding and half-life extension, and Aib substitutions at positions 2 and 13 conferring DPP-4 resistance.

Imbalanced agonism

Published receptor pharmacology describes tirzepatide as having affinity for the GIP receptor comparable to native GIP, while its GLP-1 receptor affinity is substantially weaker than native GLP-1 — roughly fivefold lower in reported binding assays.

It is therefore an imbalanced dual agonist, weighted toward GIP. Study designs that treat it as equipotent at both receptors will misattribute effects.

At the GLP-1 receptor, tirzepatide has been reported to show biased signaling favoring cAMP accumulation over β-arrestin recruitment, with reduced receptor internalization. Whether this bias accounts for observed differences against selective GLP-1 agonists is an open and actively studied question.

The GIP receptor question

A genuine and unresolved controversy in the field: both GIP receptor agonism and antagonism have been reported to produce similar metabolic effects in preclinical models. Proposed reconciliations include sustained agonism producing functional receptor desensitization — effectively acting as antagonism downstream.

This is worth knowing before designing a study around assumed GIP receptor directionality. The mechanism is not settled.

Laboratory handling

Store lyophilized at -20°C protected from light; reconstituted solution at 2-8°C for approximately 30 days.

Reconstitute with bacteriostatic water directed down the vial wall, swirling gently. Do not vortex.